Abstract:Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. The impairment of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH), adrenal hyperplasia, and excessive androgen synthesis. The syndrome is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency. The clinical manifestations of CAH in adults result from adrenocortical and adrenomedullary insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids used for the treatment of the condition. Non-classic CAH may sometimes be asymptomatic. In patients with classic CAH obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia are more often seen than in the general population. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction, and cardiovascular disease. Long-term glucocorticosteroid treatment is also a known risk factor for osteoporosis. Patients with CAH require constant monitoring of biochemical parameters (17a-hydroxyprogesterone [17-OHP] and androstenedione), clinical parameters (body mass, waist circumference, blood pressure, glucose, and lipids), and bone mineral density by densitometry. The principal goal of treatment in adults with CAH is to improve quality of life, ensure that they remain fertile, reduce the manifestations of hyperandrogenisation in females, and minimise the adverse effects of glucocorticosteroid treatment. Patients with classic CAH require treatment with glucocorticosteroids and, in cases of salt wasting, also with a mineralocorticosteroid. Radical measures, such as bilateral adrenalectomy, are very rarely needed. Asymptomatic patients with non-classic CAH require monitoring: treatment is not always necessary. Medical care for patients with CAH should be provided by reference centres, as the management of such patients requires collaboration between an endocrinologist, diabetologist, gynaecologist, andrologist, urologist, and psychologist.

Current status and prospects of congenital adrenal hyperplasia: A bibliometric and visualization study

Cardiometabolic Aspects of Congenital Adrenal Hyperplasia

Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis

Development in diagnosis and treatment of congenital adrenocortical hyperplasia

A3309 Clinical and Genetic Analysis of a Pedigree with Congenital Adrenal Hyperplasia (17Α-Hydroxylase /17,20-Lyase Deficiency) Literature

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults

Recent progress of 11β-hydroxylase deficiency

Molecular Physiopathology, Late Diagnoses, and Personalized Management

Congenital adrenal hyperplasia disorder due to 17 α-hydroxylase deficiency: a case report

Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care

Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia

Treatment for Congenital Adrenal Hyperplasia with 21-Hydroxylase Deficiency

Landscape of congenital adrenal hyperplasia cases in adult endocrinology clinics of Türkiye-a nation-wide multicentre study

Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?

Congenital Adrenal Hyperplasia - A Comprehensive Review of Genetic Studies on 21-Hydroxylase Deficiency from India

Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Prenatal diagnosis and in utero treatment of congenital adrenal hyperplasia: An up‐to‐date comprehensive review

Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia

Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management

Retrospective Analysis of Early Treatment of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Models of Congenital Adrenal Hyperplasia for Gene Therapies Testing